Lymphoblastic T-cell lymphoma (T-LBL) are the second most common subtype of non-Hodgkin lymphoma (NHL) in children and adolescents. Currently event-free survival rates (pEFS) of 75-85% can be achieved for pediatric patients. The problem, however, is the poor prognosis in case of recurrence. Only about 10-20% of these children can be treated successfully.
The present project provides a first comprehensive and detailed approach for a systematical analysis of the genomic aberrations in pediatric T-LBL by Next Generation Sequencing, in order to get a better understanding of the disease origin and pathways.
The aim is, to improve the prognosis in high-risk patients through a targeted therapy intensification and reduce the acute and long-term toxicity in low risk patients by a de-escalation of therapy.